GLEN ALLEN, Va., July 18, 2012 /PRNewswire/ -- Star Scientific,
Inc. (NASDAQ: CIGX) today announced plans for the production and
sale of its new Anatabloc® face cream. The company
anticipates a launch of the product during the third quarter of
this year.
(Logo:
http://photos.prnewswire.com/prnh/20120301/NE62741LOGO )
The Anatabloc® face cream is based upon the company's prior work
with anatabine and its anatabine citrate formulation.
Anatabine is an alkaloid found in Solanaceous plants, including
tomatoes, peppers, eggplants, and tobacco, and has properties that
improve the appearance of the skin. Anatabine citrate has
been under consideration for use in the face cream since the
systemic and topical safety of this natural ingredient was
established. After a year of product development, which
included efforts to find suitable bases for the product,
consultation with several eminent dermatologists, and evaluation of
pilot formulations of the cream, the company has created an
effective product with promising results for the skin.
Dr. Curtis Wright, Senior Vice
President and Medical/Clinical Director of Star Scientific's wholly
owned subsidiary Rock Creek Pharmaceuticals Inc., stated, "We think
that anatabine has been a helpful and useful nutritional supplement
and it is very exciting that there is a completely unexpected new
cream based on anatabine and anatabine citrate products. I
have personally reviewed the pilot work, and the results of this
new Anatabloc® face cream in improving the appearance of the skin
in subjects have been impressive."
It is anticipated that initially the Anatabloc® face cream will
be available on-line through the company's website
www.anatabloc.com and in select dermatology practices. The
Anatabloc® face cream is a natural extension of the work that the
company has been involved with in connection with its Anatabloc®
dietary supplement for anti-inflammatory support. Anatabloc® can be
purchased in all GNC corporate stores and in select franchise
stores, as well as online at www.anatabloc.com or
www.gnc.com.
Certain statements contained in this release constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements identified by words such as
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, results of clinical trials, the challenges inherent in
new product development initiatives, including the continued
development and market acceptance of our nutraceutical and low-TSNA
tobacco products, our ability to license and protect our
intellectual property, our ability to raise additional capital in
the future that is necessary to maintain our business, changes in
government policy and/or regulation, including with respect to our
nutraceutical and low-TSNA tobacco products, as well as other risks
discussed from time to time in our filings with the Securities and
Exchange Commission, including, without limitation, our annual
report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update
any forward-looking statement or any information contained in this
press release or in other public disclosures at any time.
About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a
mission to promote maintenance of a healthy metabolism, as well as
to reduce the harm associated with the use of tobacco at every
level. Over the last several years, through its wholly owned
subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been
engaged in the manufacturing, sale, and marketing of two
nutraceutical dietary supplements, and the development of other
nutraceuticals and pharmaceuticals. The company also has continued
to pursue the development, implementation, and licensing of the
technology behind its proprietary StarCured® tobacco curing
process, which substantially prevents the formation of carcinogenic
toxins present in tobacco and tobacco smoke, primarily the
tobacco-specific nitrosamines, or TSNAs and related low-TSNA
dissolvable tobacco products. Rock Creek Pharmaceuticals has
scientific and research offices in Gloucester, MA, and a regulatory office in
Washington, DC. Star
Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific &
Regulatory Affairs office in Bethesda,
MD, and a manufacturing facility in Chase City, VA.
Contact:
Talhia T. Tuck
Vice President, Communications and Investor Relations
Star Scientific, Inc.
(301) 654-8300
ttuck@starscientific.com
SOURCE Star Scientific, Inc.